Literature DB >> 28963081

Identification of mutations in the prostaglandin transporter gene SLCO2A1 and phenotypic comparison between two subtypes of primary hypertrophic osteoarthropathy (PHO): A single-center study.

Yanfang Hou1, Yuanyuan Lin2, Xuan Qi2, Lu Yuan2, Ruoxi Liao2, Qianqian Pang2, Lijia Cui2, Yan Jiang2, Ou Wang2, Mei Li2, Jin Dong3, Weibo Xia4.   

Abstract

Primary hypertrophic osteoarthropathy (PHO) is an inherited disease characterized by digital clubbing, periostosis, and pachydermia. Based on two causative genes, hydroxyprostaglandin dehydrogenase (HPGD) and solute carrier organic anion transporter family member 2A1 (SLCO2A1), PHO is categorized into two subtypes: hypertrophic osteoarthropathy, primary, autosomal recessive 1 (PHOAR1) and hypertrophic osteoarthropathy, primary, autosomal recessive 2 (PHOAR2). In this study, we summarized the clinical manifestations and analyzed SLCO2A1 gene in 23 PHOAR2 patients in our center. As a result, 18 patients displayed complete phenotypes of PHO with digital clubbing, periostosis, and pachydermia. 29 mutations were found in total, and 22 of them were novel mutations including 13 missense, three nonsense, four deletion, one frame-shift and one splicing site mutations. Compared with nine PHOAR1 patients we previously reported, PHO patients with SLCO2A1 mutations were all male and presented with a later onset age. Peptic ulcers and myelofibrosis occurred only in PHOAR2 patients. The urinary level of prostaglandin E2 metabolite (PGEM) is significantly higher in PHOAR2 patients than that in PHOAR1 group. In conclusion, this study was the largest cohort to date to summarize PHOAR2 patients and to assess the phenotypic difference between two subtypes of PHO. The difference of urinary PGEM concentration between two subtypes is helpful for the differential diagnosis of PHO.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Phenotypic comparison; Primary hypertrophic osteoarthropathy; SLCO2A1

Mesh:

Substances:

Year:  2017        PMID: 28963081     DOI: 10.1016/j.bone.2017.09.015

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

1.  Impaired bone microarchitecture in distal interphalangeal joints in patients with primary hypertrophic osteoarthropathy assessed by high-resolution peripheral quantitative computed tomography.

Authors:  Q Pang; Y Xu; X Qi; L Huang; V W Hung; J Xu; R Liao; Y Hou; Y Jiang; W Yu; O Wang; M Li; X Xing; W Xia; L Qin
Journal:  Osteoporos Int       Date:  2019-10-23       Impact factor: 4.507

2.  The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.

Authors:  Qianqian Pang; Yuping Xu; Xuan Qi; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Ling Qin; Weibo Xia
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335

3.  Pachydermoperiostosis: A clinicopathological description.

Authors:  Seyed Ali Tabatabaei; Ahmad Masoomi; Mohammad Soleimani; Seyed Mohsen Rafizadeh; Mirataollah Salabati; Aliasghar Ahmadraji; Bahram Bohrani; Hossein Ghahvechian; Zohreh Nozarian
Journal:  J Curr Ophthalmol       Date:  2019-03-29

4.  Primary hypertrophic osteoarthropathy related gastrointestinal complication has distinctive clinical and pathological characteristics: two cases report and review of the literature.

Authors:  Qiang Wang; Ying-He Li; Guo-le Lin; Yue Li; Wei-Xun Zhou; Jia-Ming Qian; Wei-Bo Xia; Dong Wu
Journal:  Orphanet J Rare Dis       Date:  2019-12-26       Impact factor: 4.123

5.  A novel mutation in the SLCO2A1 gene, encoding a prostaglandin transporter, induces chronic enteropathy.

Authors:  Keisuke Jimbo; Toshiaki Okuno; Ryuichi Ohgaki; Kou Nishikubo; Yuri Kitamura; Yumiko Sakurai; Lili Quan; Hiromichi Shoji; Yoshikatsu Kanai; Toshiaki Shimizu; Takehiko Yokomizo
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

6.  Characterization of Mineral and Bone Metabolism Biomarkers in a Chinese Consanguineous Twin Family with Primary Hypertrophic Osteoarthropathy.

Authors:  Na Li; Yuhang Ma; Yun Jiang; Li You; Yunhong Huang; Yongde Peng; Xiaoying Ding; Li Zhao
Journal:  Int J Endocrinol       Date:  2020-12-03       Impact factor: 3.257

7.  Novel SLCO2A1 mutations cause gender differentiated pachydermoperiostosis.

Authors:  Lijuan Yuan; Xihui Chen; Ziyu Liu; Dan Wu; Jianguo Lu; Guoqiang Bao; Sijia Zhang; lIfeng Wang; Yuanming Wu
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

8.  Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial.

Authors:  Lu Yuan; Ruo-Xi Liao; Yuan-Yuan Lin; Yan Jiang; Ou Wang; Mei Li; Xiao-Ping Xing; Qian-Qian Pang; Evelyn Hsieh; Wei-Bo Xia
Journal:  J Orthop Translat       Date:  2018-10-31       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.